Reference to Oral-lyn in 2/5 call...
Generex Investor Call Feb. 05, 2021 - Page 13 of 17
James Williams: Yes, sir. I just wanted to just to thank Mr. Moscato and everyone that has contributed here today for talking about all the initiatives. But my main question is in regard to Generex Oral-lyn, it's kind of like that ugly stepchild that's kind of never mentioned. And I just wanted to see if we can receive some type of updates, since it is the drug platform that is the furthest along; it has been in Phase 3 trials for about a decade now, and I just want to see, since it could possibly be the most lucrative drug in which Generex does own that's in Phase 3, can we receive some type of updates as to where that stands currently right now; and what do you expect to do with that in the next six months to the next year?
Joe Moscato: Well, what we've done is, a few years back, we reformulated Oral-lyn, we made it a much better formulation, much more effective in regard to from use perspective, much less puffs than it was before it was seven to ten puffs, now it's down to one to two puffs. So, our plan is to always get back to Oral-lyn when the second contract from China kicks in on the $50 million licensing fee for IIP; our plan was to take some of that $50 million and put it back into that program, get to the FDA and rekindle that program.
So, the Chinese contracts that we signed equals about $65 million in upfront payments licensing fees; the first one is the $5 million for COVID; and then the second one is the $50 million for the Ii-Key platform. That's all-free cash when we get that, and we do plan on putting some of those funds back into that program because we believe it's still a viable pathway and a potential product for us in the future.
Generex Investor Call Feb. 05, 2021 Transcript:
https://storage.googleapis.com/wzukusers/user...5_2021.pdf
Generex Investor Call Feb. 05, 2021 - Page 13 of 17
James Williams: Yes, sir. I just wanted to just to thank Mr. Moscato and everyone that has contributed here today for talking about all the initiatives. But my main question is in regard to Generex Oral-lyn, it's kind of like that ugly stepchild that's kind of never mentioned. And I just wanted to see if we can receive some type of updates, since it is the drug platform that is the furthest along; it has been in Phase 3 trials for about a decade now, and I just want to see, since it could possibly be the most lucrative drug in which Generex does own that's in Phase 3, can we receive some type of updates as to where that stands currently right now; and what do you expect to do with that in the next six months to the next year?
Joe Moscato: Well, what we've done is, a few years back, we reformulated Oral-lyn, we made it a much better formulation, much more effective in regard to from use perspective, much less puffs than it was before it was seven to ten puffs, now it's down to one to two puffs. So, our plan is to always get back to Oral-lyn when the second contract from China kicks in on the $50 million licensing fee for IIP; our plan was to take some of that $50 million and put it back into that program, get to the FDA and rekindle that program.
So, the Chinese contracts that we signed equals about $65 million in upfront payments licensing fees; the first one is the $5 million for COVID; and then the second one is the $50 million for the Ii-Key platform. That's all-free cash when we get that, and we do plan on putting some of those funds back into that program because we believe it's still a viable pathway and a potential product for us in the future.
Generex Investor Call Feb. 05, 2021 Transcript:
https://storage.googleapis.com/wzukusers/user...5_2021.pdf
3
